Field Medical Inc., a pioneer in cardiac pulsed field ablation (PFA) technology, today announced the successful closing of ...

Field Medical Inc. reaped $40 million in its series A fundraising via $20 million in new capital and conversion of $20 ...

The biomedical market’s latest technology for treating irregular heartbeats has made its way to the Flathead Valley, bringing ...

Catheter Ablation Devices for Atrial Fibrillation Market 2035, Driven by advanced devices, better clinical outcomes, and rising regulatory approvals.

Pulse Biosciences is developing nsPFA technology for cardiac ablation to treat AFib and for ablating benign thyroid nodules.

Atrial fibrillation is frequently treated with ablation – a procedure where doctors create small, controlled scars to block ...

Atrial fibrillation is frequently treated with ablation -- a procedure where doctors create small, controlled scars to block erratic electrical signals. However, success rates vary considerably ...

One of AI’s most immediate impacts is in screening and identifying patients who may have asymptomatic or paroxysmal AF, those ...

Vektor Medical, a leader in non-invasive, AI-powered arrhythmia analysis technology, today announced the initiation of the ...

A novel diffusion model generates synthetic atrial fibrosis images to augment data for deep learning, improving prediction of ...

The global atrial fibrillation market is projected to witness robust growth over the next decade. In 2023, the market generated a substantial revenue of US$ 3,505.7 million and is estimated to achieve ...

The FieldForce™ Ablation System is an investigational device and is limited by federal (or United States) law to investigational use. Ventricular tachycardia (VT) and atrial fibrillation (AF ...